Citations

Clear

4847 citation(s) found for "Tu, Eric".

Tracking Pleomorphic Adenoma Incidence Trends Over 47 Years: A Population‐Based Study
Rourk, Katelyn S. , Daher, Ghazal S. , Schwartz, Jenna R., Ali, Hawa M. , Shurtz, Anne K., Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Van Abel, Kathryn M , Rourk, Katelyn , Schwartz, Jenna R., Price, Daniel L. , Yin, Linda X.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | May 5, 2025 | Volume: 173 | Issue: 3 | Pages: 651-659

10.1002/ohn.1292 | PMID 40323181 Get It

Abstract Objective To (1) track the incidence of pleomorphic adenomas (PAs) and (2) compare demographic and treatment trends in PAs over the last five decades in a single county. Study Design Retrospective cohort of all patients with a pathologic diagnosis of nonrecurrent PA from January 1976 to December 2022. Setting Olmsted County, Minnesota. Methods Incidence was calculated per 100,000 persons/year and age and sex‐adjusted to the US 2020 census data. Incidence trends were identified using Poisson rate regression models. Changes in clinical features of diagnosis were evaluated using Spearman rank correlation coefficient tests, Wilcoxon rank sum tests, and Kruskal‐Wallis tests. Results In total, 251 patients with PA were identified. The median age at diagnosis was 50.0 years with a slight female predominance (1.24:1). The adjusted incidence during this period is 4.79/100,000 person‐years, increasing from 2.50 in 1976 to 1979 to 5.73/100,000 persons/year in 2020 to 2022. Less extensive surgery, including partial and superficial parotidectomies, increased significantly from 1976 to 2022, whereas total parotidectomies decreased ( P < .0001). The number of patients who presented with an incidental imaging finding increased during this time period ( P < .001), as did the age at diagnosis (45‐51 years, P = .05) Conclusion The average annual incidence of PAs in Olmsted County from 1976 to 2022 is higher than reported US estimates and has increased over the last five decades. The percentage of patients who presented with incidental imaging findings increased over this period, as did the age at diagnosis. These findings highlight modern imaging techniques and an aging population more willing to seek workup and treatment of a benign parotid mass.
Oncological Efficacy and Postoperative Outcomes of Low Grade Mucoepidermoid Carcinoma Treated With Partial Parotidectomy
Ali, Hasnat , Rourk, Katelyn S. , Byrne, Jamie O., Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Ali, Hawa M , Van Abel, Kathryn M , Yin, Linda X , Price, Daniel L. , Yin, Linda X.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 5, 2025 | Volume: 134 | Issue: 8 | Pages: 606-612

10.1177/00034894251335405 | PMID 40320862 Get It

Objective: To assess the impact of extent of parotidectomy on surgical and oncologic outcomes in low grade mucoepidermoid carcinoma (LGMEC). Methods: A retrospective chart review of all patients undergoing primary surgical treatment for LGMEC from 2000 to 2022 was conducted. Clinical features collected included demographics, facial nerve function, operative techniques, postoperative complications/facial nerve function, and recurrence. Results: 58 patients were included; 10 patients underwent partial parotidectomy (PP), 38 underwent superficial parotidectomy (SP), and 10 underwent near-total/total parotidectomy. PP and SP patients had smaller tumors and more superficial tumors compared to near-total/total parotidectomy group ( P = .03). PP and SP were more likely to have negative margins and less locoregional disease compared to near-total/total parotidectomy patients ( P < .01). Near-total/total parotidectomy were more likely to undergo facial nerve resection (20% vs 0% for PP & SP respectively) ( P = .05). Immediate postoperative facial nerve function was significantly better among PP patients (73% HB I) compared to SP (44% HB I) and near-total/total parotidectomy patients (0% HB I) ( P < .01). Most patients regained their facial nerve function although only 40% of the near-total/total parotidectomy patients had a HB I at the time of last follow up ( P < .01). Patients were followed for a median of 6.2 years, during which only 1 patient (total parotidectomy) had a recurrence. Conclusions: PP offers a safe and effective approach for small LGMEC tumors, ensuring better facial nerve function postoperatively with minimal complications compared to more extensive surgery.
Clinical phenotypes among patients with familial forms of Chiari malformation type 1
Mekbib, Kedous Y. , Allington, Garrett , Zhao, Shujuan, Fortes, Carla, Shohfi, John, Nelson‐Williams, Carol , Butler, William E. , Alper, Seth L. , Jackson, Eric M., Muñoz, William , Mehta, Neel H. , Fan, Baojian , DeSpenza, Tyrone , Kahle, Kristopher T.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | May 2, 2025 | Volume: 36 | Issue: 1 | Pages: 109-118

10.3171/2025.1.peds24187 | PMID 40315599 Get It

OBJECTIVE Chiari malformation type 1 (CM1) is the most common neurological disorder of the craniocervical junction. CM1 is characterized by cerebellar tonsillar herniation below the foramen magnum, causing CSF obstruction and neural compression. Patients with CM1 suffer from highly variable symptoms, progression, comorbidities, and outcomes, partly due to poor understanding of CM1 pathogenesis. In this paper, the authors present the only familial CM1 cohort study to statistically assess intrafamilial clinical phenotypes to date. METHODS Comprehensive medical, surgical, and family histories and neuroimaging were collected from families with multiple CM1-affected family members. Univariate analysis was performed for each symptom, comorbidity, or surgery to compare observed versus expected frequencies of affected patients with another CM1-affected family member with the same clinical characteristic. RESULTS Twenty-four new familial CM1 cases (totaling 57 patients with CM1) are presented. Intrafamilial similarities were identified for age of onset, symptoms such as headaches (p = 0.007) and neck pain (p = 0.018), neurological comorbidities such as syringomyelia (p = 0.003) and hydrocephalus (p = 0.0001), neurodevelopmental conditions such as dyslexia (p < 0.0001), and connective tissue disorders (CTDs) such as Ehlers-Danlos syndrome (p < 0.0001). CONCLUSIONS These results suggest that CM1 and its associated clinical phenotypes, including age of onset, clinical symptoms, neurological comorbidities, neurodevelopmental conditions, and CTDs, are genetically influenced. Whole-exome sequencing of CM1 patient-parent trios has the potential to identify the genetic determinants of CM1, with implications for neurosurgical management.
UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP
Tian, Shulan , Jenkinson, Garrett , Ferrer, Alejandro Tiana, Yan, Huihuang , Morales‐Rosado, Joel A. , Wang, Kevin L. , Lasho, Terra L. , Yan, Benjamin B. , Baheti, Saurabh , Olson, Janet E. , Patnaik, Mrinal M. , Klee, Eric W. , Ferrer, Alejandro , Ferrer, Alejandro , Baughn, Linda B , Ding, Wei , Slager, Susan L , Patnaik, Mrinal , Lazaridis, Konstantinos N , Klee, Eric W , Olson, Janet E , Lasho, Terra L , Tian, Shulan , Morales-Rosado, Joel A , Baughn, Linda B. , Slager, Susan L. , Lazaridis, Konstantinos N.

Mayo Clinic

Genomics, Proteomics & Bioinformatics | April 29, 2025 | Volume: 23 | Issue: 2 | Pages: No page available

10.1093/gpbjnl/qzaf040 | PMID 40300108 Get It

Abstract Clonal hematopoiesis (CH) of indeterminate potential (CHIP), driven by somatic mutations in leukemia-associated genes, confers increased risk of hematologic malignancies, cardiovascular disease, and all-cause mortality. In blood of healthy individuals, small CH clones can expand over time to reach 2% variant allele frequency (VAF), the current threshold for CHIP. Nevertheless, reliable detection of low-VAF CHIP mutations is challenging, often relying on deep targeted sequencing. Here, we present UNISOM, a streamlined workflow for enhancing CHIP detection from whole-genome and whole-exome sequencing data that are underpowered, especially for low VAFs. UNISOM utilizes a meta-caller for variant detection, in couple with machine learning models which classify variants into CHIP, germline, and artifact. In whole-exome sequencing data, UNISOM recovered nearly 80% of the CHIP mutations identified via deep targeted sequencing in the same cohort. Applied to whole-genome sequencing data from Mayo Clinic Biobank, it recapitulated the patterns previously established in much larger cohorts, including the most frequently mutated CHIP genes and predominant mutation types and signatures, as well as strong associations of CHIP with age and smoking status. Notably, 30% of the identified CHIP mutations had &lt; 5% VAFs, demonstrating its high sensitivity toward small mutant clones. This workflow is applicable to CHIP screening in population genomic studies. The UNISOM pipeline is freely available at https://github.com/shulanmayo/UNISOM and https://ngdc.cncb.ac.cn/biocode/tool/7816.
Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1 , BRCA2 , ATM , C
Kurian, Allison W. , Hughes, Elisha , Bernhisel, Ryan , Hu, Eudora , Polley, Eric C. , Yadav, Siddhartha , Caswell‐Jin, Jennifer L. , John, Esther M. , Shadyab, Aladdin H. , Chlebowski, Rowan T. , Hu, Chunling , Caswell-Jin, Jennifer L , John, Esther M , Shadyab, Aladdin H , Chlebowski, Rowan , Nassir, Rami , Kraft, Peter , Stefanick, Marcia L , Couch, Fergus J. , Yadav, Siddhartha , Polley, Eric C , Kurian, Allison W , Hu, Chunling , Nassir, Rami , Kraft, Peter , Couch, Fergus J.

Mayo Clinic

Cancer Research Communications | April 29, 2025 | Volume: 5 | Issue: 5 | Pages: 783-791

10.1158/2767-9764.crc-24-0592 | PMID 40298171 Get It

Abstract There are limited prospective data on whether established risk factors modify breast cancer risk in women with pathogenic variants (PV) in BRCA1/2 and virtually no risk modification data for ATM, CHEK2, or PALB2. We conducted a nested case–control study in the Women’s Health Initiative (WHI), randomly selecting women with and without breast cancer for DNA sequencing. We evaluated breast cancer odds associated with obesity, family cancer history, smoking, alcohol, parity, breastfeeding, oophorectomy, tubal ligation, neighborhood socioeconomic status, and menopausal hormone therapy (MHT) with estrogen and progestin or estrogen only in PV carriers and noncarriers. In exploratory analyses, we grouped genes by established predisposition for estrogen receptor (ER)-positive (ATM and CHEK2) or ER-negative (BRCA1 and PALB2) disease. Multivariable models with interaction terms were used to assess differential risk modification by PVs. Among 12,957 WHI participants, 287 carried PVs. Breastfeeding was modestly associated with reduced risk for PALB2 [OR = 0.08; 95% confidence interval (CI), 0.00–0.92; P value = 0.042]. With one-sided 95% CI, power was sufficient to exclude OR ≥2.0 with obesity for ATM and BRCA2; smoking and alcohol for CHEK2; no breastfeeding for ATM; no oophorectomy for BRCA2 and CHEK2; no tubal ligation for CHEK2; and neighborhood socioeconomic status for all genes. Estrogen + progestin MHT was modestly associated with increased risk for ER-positive PVs (OR = 7.31; 95% CI, 1.14–64.20; P = 0.036). PVs did not modify risk (interaction P ≥ 0.05). BRCA1/2, ATM, CHEK2, and PALB2 PV carriers do not have breast cancer OR ≥2.0 with many established risk factors. However, MHT warrants additional study in PV carriers. Significance: There is limited information on whether established risk factors increase breast cancer risk from PVs. In the WHI, PV carriers had no substantial (≥2-fold) increase with most risk factors, except potentially MHT in ATM or CHEK2 carriers. The results may inform counseling and research on MHT.
Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Shallis, Rory M. , Winer, Eric S. , Badar, Talha , Swaroop, Alok , Doukas, Peter H., Geramita, Emily , Agarwal, Sonal , Merl, Man Yee, Im, Annie , Litzow, Mark R. , Badar, Talha , Swaroop, Alok , Weiss, Julian J , Doukas, Peter, Le, Henry, Abaza, Yasmin , Podoltsev, Nikolai

Mayo Clinic

Leukemia & Lymphoma | April 28, 2025 | Volume: 66 | Issue: 9 | Pages: 1735-1739

10.1080/10428194.2025.2496339 | PMID 40294060 Get It

Micropulse Transscleral Laser Treatment Versus Continuous Wave Transscleral Cyclophotocoagulation for the Treatment of Glaucoma or Ocular Hypertension: A Meta-Analysis
Chavez, Matheus Pedrotti , Guedes, Guilherme Barroso , Pasqualotto, Eric , Almeida, Izabela , Souza, Tiago Tomaz de , Chavez, Matheus P , Lopes, Lucca Moreira , Prata, Tiago S.

Mayo Clinic

Journal of Glaucoma | April 28, 2025 | Volume: 34 | Issue: 8 | Pages: 575-584

10.1097/ijg.0000000000002583 | PMID 40293349 Get It

Précis: Micropulse transscleral laser treatment (MP-TLT) and continuous wave transscleral cyclophotocoagulation demonstrated comparable intraocular pressure across all follow-ups. MP-TLT was associated with significantly lower risks of ocular complications, such as hypotony, prolonged inflammation, and phthisis bulbi. Purpose: To compare the efficacy and safety of micropulse transscleral laser treatment (MP-TLT) and continuous wave transscleral cyclophotocoagulation (CW-TSCPC) for the treatment of glaucoma or ocular hypertension. Methods: A systematic search was conducted in PubMed, Cochrane Library, Embase, and ClinicalTrials.gov. Randomized controlled trials (RCTs) or cohort studies comparing MP-TLT and CW-TSCPC were included. Weighted mean differences (MDs) were computed for continuous endpoints and risk ratios (RRs) for binary endpoints, with 95% CIs. Heterogeneity was assessed with I 2 statistics. Software R, version 4.4.0, was used for statistical analyses. Subgroup analyses were conducted on glaucoma types. Results: Eleven studies encompassing 1054 eyes from 986 patients were included, with 47.4% receiving MP-TLT. There were no significant differences in IOP between CW-TSCPC and MP-TLT at 1 week, 1 month, 3 months, 6 months, 12 months, and 18 months of follow-up. The MP-TLT group required a significantly higher number of hypotensive medications but displayed significantly reduced risks of overall complications, ocular hypotony, prolonged inflammation, and phthisis bulbi compared with CW-TSCPC. Conclusion: MP-TLT and CW-TSCPC showed similar efficacy in IOP control. However, MP-TLT demonstrated a greater safety profile, suggesting its potential suitability for patients requiring repeat interventions or those with lower tolerance for ocular complications.
Neuromuscular Ultrasound Assessment of the Median Nerve at the Wrist and Forearm: A Reproducibility and Reliability Study in Nonphysician Sonographers
Meiling, James B. , Boon, Andrea J. , Sorenson, Eric J. , Litchy, William J. , Meiling, James B

Mayo Clinic

Muscle & Nerve | April 28, 2025 | Volume: 72 | Issue: 1 | Pages: 130-133

10.1002/mus.28424 | PMID 40289532 Get It

ABSTRACTIntroduction/AimsNeuromuscular ultrasound (NMUS), initially performed by physicians, is increasingly performed by technicians in many electrodiagnostic (EDX) laboratories for certain studies under physician supervision. The aims of this study were to determine: (1) the reproducibility of nonphysician sonographers' assessments of the median nerve and (2) the need for ongoing training to maintain the reproducibility and reliability of median nerve ultrasound assessments.MethodsThe median nerve was examined sonographically in a healthy volunteer by 12 nonphysicians on 3 separate occasions: Day 1 and then 2 weeks (Day 2) and 4 months (Day 3) later. Cross‐sectional area (CSA) and wrist‐to‐forearm ratios (WFRs) were calculated each time. Sonographers were retrained prior to Day 2. Reproducibility and reliability were determined using coefficients of variation calculated for each characteristic for each day and each nonphysician sonographer, comparing performance across the 3 time points.ResultsThere was overall less variation for each characteristic (wrist CSA, forearm CSA, and WFR) on Day 2 compared to Day 1 (coefficients of variation 3.0%, 5.4%, and 5.7% vs. 8.8%, 15.5%, and 11.3%, respectively), both when viewed at the group and individual levels, indicating an improvement in reproducibility and reliability after the retraining session. The improvement was similar for Day 3.DiscussionThis study demonstrates the need for training and subsequent retraining sessions to ensure the reproducibility and reliability of NMUS measurements in the median nerve.
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Bando, Hideaki , Takeda, Yuriko , Misumi, Toshihiro , Nishikawa, Tomomi, Wakabayashi, Masashi , Yamazaki, Kentaro , Oki, Eiji , Douillard, Jean‐Yves , Punt, Cornelis J. A. , Koopman, Miriam , Bokemeyer, Carsten , Lenz, Heinz‐Josef , Maehara, Yoshihiko , Gramont, Aimery de, Yoshino, Takayuki , Van Cutsem, Eric , Venook, Alan P , Lenz, Heinz-Josef , Maehara, Yoshihiko , André, Thierry , Shi, Qian , De Gramont, Aimery , Yoshino, Takayuki , Oki, Eiji , Bando, Hideaki , Cutsem, Eric Van , Venook, Alan P. , André, Thierry , Shi, Qian , Gramont, Aimery de

Mayo Clinic

JNCI Cancer Spectrum | April 26, 2025 | Volume: 9 | Issue: 3 | Pages: No page available

10.1093/jncics/pkaf042 | PMID 40280867 Get It

Abstract Background Early tumor shrinkage and depth of response have emerged as potential prognostic indicators in metastatic colorectal cancer (CRC). However, their associations with overall survival, progression-free survival (PFS), and postprogression survival in patients receiving anti–epidermal growth factor receptor (EGFR) antibodies or bevacizumab remain unclear. Methods We analyzed 3219 treatment-naive patients with RAS wild-type metastatic CRC from 8 randomized studies (CRYSTAL, OPUS, PRIME, CAIRO2, CALGB80405, WJOG4407G, ATOM, PARADIGM) in the Aid and Research in Digestive Cancerology database. Early tumor shrinkage was defined as a 20% or more reduction in tumor size at 8 ± 2 weeks, whereas depth of response was assessed by maximum tumor shrinkage at nadir. Cox regression models evaluated the associations of early tumor shrinkage and depth of response with overall survival, PFS, and postprogression survival, adjusting for confounders. A 2-sided test was conducted with a significance level of .05. Results Early tumor shrinkage and depth of response substantially stratified overall survival, PFS, and postprogression survival outcomes across all treatment groups. Early tumor shrinkage positivity was associated with improved overall survival, PFS, and postprogression survival in anti-EGFR and bevacizumab-based therapies, with a trend toward better outcomes in the anti-EGFR group. The depth of response analysis revealed optimal cutoff values of 0.55 for anti-EGFR–based therapy and 0.47 for bevacizumab-based therapy to achieve a median overall survival of approximately 32 months. Conclusions Early tumor shrinkage and depth of response serve as valuable prognostic markers in RAS wild-type metastatic CRC, particularly for patients treated with anti-EGFR antibodies. These findings highlight the potential role of early tumor shrinkage and depth of response in guiding treatment strategies and improving outcomes for patients with CRC.
92. Can We Innovate the Teaching of Facial Anatomy for Aesthetic Surgery Using 3D Photogrammetry and Immersive Virtual Reality
Hussein, Sara , Emanuels, Andrew F., Leonel, Luciano, Lachman, Nirusha , Celda, María Peris, Sheahan, Eric M., Martinez, Erick O., Emanuels, Andrew, Morris, Jonathan M. , Martinez, Erick O., Hanson, Christian R., Sharaf, Basel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 25, 2025 | Volume: 13 | Issue: S1 | Pages: 64-64

10.1097/01.gox.0001112320.62413.e9 Get It